Nektar Therapeutics Reports Positive Phase 2b Trial Results for Hair-Loss Drug, Driving Stock Higher
Nektar Therapeutics (NKTR) reported positive results from a phase 2b trial of its drug rezpegaldesleukin for treating severe alopecia areata, leading to an 18.25% surge in its stock. The trial showed improved hair growth in patients who had previously responded to the treatment, following a prior study affected by enrollment errors. The company plans to advance the drug into later-stage trials.
Tickers: $NKTR
Topics: clinical trial hair-loss treatment Nektar Therapeutics rezpegaldesleukin stock performance